Sulforaphane protects H9c2 cardiomyocytes from angiotensin II-induced hypertrophy

Herz

Volumn 39, Issue 3, 2014, Pages 390-396

  Wu, Q Q ^a,b   Zong, J ^a,b   Gao, L ^c   Dai, J ^a,b   Yang, Z ^a,b   Xu, M ^a,b   Fang, Y ^a,b   Ma, Z G ^a,b   Tang, Q Z ^a,b  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^b WUHAN UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Angiotensin II; Cardiac hypertrophy; Cardiomyocytes; H9c2 cells; Sulforaphane

Indexed keywords

ALPHA ACTININ; ANGIOTENSIN II; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; GLYCOGEN SYNTHASE KINASE 3BETA; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INITIATION FACTOR 4E; MAMMALIAN TARGET OF RAPAMYCIN; MYOSIN HEAVY CHAIN BETA; SULFORAPHANE; CARDIOTONIC AGENT; ISOTHIOCYANIC ACID DERIVATIVE; ONCOPROTEIN; SULFORAFAN;

ANGIOTENSIN II INDUCED CARDIAC HYPERTROPHY; ANIMAL CELL; ARTICLE; CELL PROTECTION; CELL SURFACE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG INDUCED DISEASE; GENE EXPRESSION REGULATION; HEART MUSCLE CELL; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; NONHUMAN; PROTEIN DEGRADATION; PROTEIN SYNTHESIS INHIBITION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SURFACE PROPERTY; WESTERN BLOTTING; ANIMAL; CELL LINE; CELL SIZE; CELL SURVIVAL; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; HYPERTROPHY, LEFT VENTRICULAR; METABOLISM; PATHOLOGY; TREATMENT OUTCOME;

ANGIOTENSIN II; ANIMALS; CARDIOTONIC AGENTS; CELL LINE; CELL SIZE; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTROPHY, LEFT VENTRICULAR; ISOTHIOCYANATES; MYOCYTES, CARDIAC; NF-KAPPA B; ONCOGENE PROTEIN V-AKT; RATS; TREATMENT OUTCOME;

EID: 84901362006     PISSN: 03409937     EISSN: 16156692     Source Type: Journal    
DOI: 10.1007/s00059-013-3849-4     Document Type: Article

References (22)

1. Izzo JL Jr, Gradman AH (2004) Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure. Med Clin North Am 88:1257-1271
2. Rohini A, Agrawal N, Koyani CN, Singh R (2010) Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 61:269-280
3. Barry SP, Davidson SM, Townsend PA (2008) Molecular regulation of cardiac hypertrophy. Int J Biochem Cell Biol 40:2023-2039
4. Empel VP van, De Windt LJ (2004) Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc Res 63:487-499 (Pubitemid 38970193)
5. Clerk A, Cullingford TE, Fuller SJ et al (2007) Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 212:311-322 (Pubitemid 47025620)
6. Shioi T, McMullen JR, Kang PM et al (2002) Akt/protein kinase B promotes organ growth in transgenic mice. Mol Cell Biol 22:2799-2809 (Pubitemid 34263000)
7. Purcell NH, Tang G, Yu C et al (2001) Activation of NF-kappa B is required for hypertrophic growth of primary rat neonatal ventricular cardiomyocytes. Proc Natl Acad Sci U S A 98:6668-6673 (Pubitemid 32538274)
8. Fahey JW, Zalcmann AT, Talalay P (2001) The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry 56:5-51 (Pubitemid 32063165)
9. Poppel G van, Verhoeven DT, Verhagen H, Goldbohm RA (1999) Brassica vegetables and cancer prevention. Epidemiology and mechanisms. Adv Exp Med Biol 472:159-168
10. Xu T, Ren D, Sun X, Yang G (2012) Dual roles of sulforaphane in cancer treatment. Anticancer Agents Med Chem
11. Chew YC, Adhikary G, Wilson GM et al (2012) Sulforaphane induction of p21(Cip1) cyclin-dependent kinase inhibitor expression requires p53 and Sp1 transcription factors and is p53-dependent. J Biol Chem 287:16168-16178
12. Guerrero-Beltran CE, Calderon-Oliver M, Pedraza-Chaverri J, Chirino YI (2012) Protective effect of sulforaphane against oxidative stress: recent advances. Exp Toxicol Pathol 64:503-508
13. Zhu H, Jia Z, Strobl JS et al (2008) Potent induction of total cellular and mitochondrial antioxidants and phase 2 enzymes by cruciferous sulforaphane in rat aortic smooth muscle cells: cytoprotection against oxidative and electrophilic stress. Cardiovasc Toxicol 8:115-125
14. Angeloni C, Leoncini E, Malaguti M et al (2009) Modulation of phase II enzymes by sulforaphane: implications for its cardioprotective potential. J Agric Food Chem 57:5615-5622
15. Piao CS, Gao S, Lee GH et al (2010) Sulforaphane protects ischemic injury of hearts through antioxidant pathway and mitochondrial K(ATP) channels. Pharmacol Res 61:342-348
16. Vojdani Z, Tavakolinejad S, Talaei-Khozani T et al (2011) Cardiomyocyte marker expression in a human lymphocyte cell line using mouse cardiomyocyte extract. Hum Cell 24:35-42
17. Kim S, Ohta K, Hamaguchi A et al (1995) Angiotensin II induces cardiac phenotypic modulation and remodeling in vivo in rats. Hypertension 25:1252-1259
18. Hardt SE, Sadoshima J (2002) Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development. Circ Res 90:1055-1063 (Pubitemid 34627903)
19. Antos CL, McKinsey TA, Frey N et al (2002) Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. Proc Natl Acad Sci U S A 99:907-91220.
20. Aoyagi T, Matsui T (2011) Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr Pharm Des 17:1818-182421.
21. Jones WK, Brown M, Ren X et al (2003) NF-kappaB as an integrator of diverse signaling pathways: the heart of myocardial signaling? Cardiovasc Toxicol 3:229-25422.
22. Van der Heiden K, Cuhlmann S, Luong le A et al (2010) Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 118:593-605